Literature DB >> 2502924

Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator.

G J Jaffe1, H Lewis, D P Han, G A Williams, G W Abrams.   

Abstract

We injected 25 micrograms of recombinant tissue plasminogen activator into the anterior chamber or the vitreous cavity in seven aphakic patients for pupillary block caused by a complete fibrin pupillary membrane that formed after vitrectomy with fluid-gas exchange. Progressive fibrin deposition resulted in pupillary block by three days after vitrectomy surgery in six patients, and seven days after vitrectomy in one patient. The pupillary block was associated with increased intraocular pressure in six patients. Tissue plasminogen activator was injected via the corneoscleral limbus in five patients and via the pars plana in two patients. In all patients, injection of tissue plasminogen activator resulted in complete fibrinolysis of the fibrin pupillary membrane within four hours, associated with a deepening of the anterior chamber. In the six patients with increased intraocular pressure at the time of tissue plasminogen activator injection, dissolution of the fibrin membrane was associated with a decrease in pressure. In all patients, intraocular pressure had returned to normal by three days after the injection. No complications were associated with the injection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502924     DOI: 10.1016/0002-9394(89)90013-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Tissue plasminogen activator therapy for the eye.

Authors:  R C Tripathi; B J Tripathi
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

2.  Plasminogen in proliferative vitreoretinal disorders.

Authors:  P Esser; K Heimann; K U Bartz-Schmidt; P Walter; R Krott; M Weller
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

3.  Recombinant tissue plasminogen activator following paediatric cataract surgery.

Authors:  J S Mehta; G G Adams
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

4.  Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery.

Authors:  H Siatiri; A H Beheshtnezhad; H Asghari; N Siatiri; S Moghimi; N Piri
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

5.  The use of tissue plasminogen activator in postvitrectomy cases.

Authors:  C Koutsandrea; M Apostolopoulos; P Theodossiadis
Journal:  Int Ophthalmol       Date:  1993-04       Impact factor: 2.031

Review 6.  Surgery for Diabetic Eye Complications.

Authors:  María H Berrocal; Luis A Acaba; Alexandra Acaba
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

7.  Promotion of glaucoma filter bleb with tissue plasminogen activator after sclerectomy under a clot.

Authors:  A Szymanski
Journal:  Int Ophthalmol       Date:  1992-09       Impact factor: 2.031

8.  Fibrin membrane pupillary-block glaucoma after uneventful cataract surgery treated with intracameral tissue plasminogen activator: a case report.

Authors:  Hideaki Yoshino; Masaaki Seki; Jun Ueda; Takaiko Yoshino; Takeo Fukuchi; Haruki Abe
Journal:  BMC Ophthalmol       Date:  2012-03-20       Impact factor: 2.209

Review 9.  Surgical management of diabetic retinopathy.

Authors:  Vishali Gupta; J Fernando Arevalo
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Oct-Dec

10.  The Nd:YAG laser as first-line treatment for fibrin pupillary-block glaucoma following uncomplicated cataract surgery.

Authors:  Selina Khan; Mohamed Elashry
Journal:  Oxf Med Case Reports       Date:  2019-01-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.